14th Annual Perspectives in Thoracic Oncology

20. 11. 2009 - 21. 11. 2009, The Westin New York at Times Square, New York, USA

Registrace

Friday, November 20, 2009
Session I: Introductory lectures
8:00 am Welcome Corey J. Langer, MD, FACP
8:05 am Keynote lecture: Lung cancer – evolving epidemiology, risk factors, and molecular genetics Paul A. Bunn, Jr., MD
8:30 am Women and lung cancer: Is it now epidemic, and should women be treated differently? Jessica S. Donington, MD
8:55 am Changing demographics of smoking and its effects during therapy Angela M. Davies, MD, FRCP
9:15 am Panel discussion
9:30 am Break
Session II: Surgery and staging
9:50 am Case presentation: Ongoing research issues in surgery
More is better Joseph B. Shrager, MD
Less is better Walter J. Scott, MD, FACS
10:20 am Cost-effective staging in NSCLC Gerard A. Silvestri, MD, MS
10:40 am Interventional bronchoscopy for the management of endobronchial lesions Michael Unger, MD, FACP, FCCP
11:00 am Panel discussion
11:15 am Lunch
Session III: Radiation oncology for the uninitiated and perpetually perplexed
12:45 pm V20 and other therapeutic parameters: What are they and how do we accommodate them? Walter J. Curran, MD, FACR
1:05 pm Stereotactic radiation: Emerging role in localized lung cancer Speaker Invited
1:25 pm Image-guided radiation therapy: Therapeutic implications and limitations Jeffrey D. Bradley, MD
1:45 pm Is there a role for adjuvant radiotherapy in resected NSCLC? Brian E. Lally, MD
2:05 pm Panel discussion
2:15 pm Break
Session IV: Adjuvant therapy
2:30 pm Selecting the appropriate patient and the adjuvant therapeutic regimen Gary M. Strauss, MD, MPH
2:50 pm Ongoing clinical trials in the adjuvant arena: Where are we heading? Speaker Invited
3:10 pm Neoadjuvant therapy for NSCLC: When is it useful? When is it not? Speaker Invited
Session V: Special topics in thoracic oncology
3:30 pm Esophageal cancer David H. Ilson, MD, PhD
3:50 pm Mesothelioma Hedy L. Kindler, MD
4:10 pm SCLC: Are we doomed to therapeutic paralysis? David S. Ettinger, MD
4:30 pm Discussion
4:45 pm Adjourn
Saturday, November 21, 2009
8:30 am Welcome to day two Corey J. Langer, MD, FACP
Session VI: Advanced NSCLC
8:40 am First-line treatment for advanced NSCLC: What is the standard? Speaker Invited
9:05 am Molecular determination of cytotoxic therapy George R. Simon, MD, FACP, FCCP
9:25 am Maintenance therapy in advanced NSCLC: Has its time arrived? Corey J. Langer, MD, FACP
9:45 am Third-line therapy and beyond Nasser H. Hanna, MD
10:10 am Break
Session VII: Therapeutic neglect in lung cancer
10:30 am Management of pleural effusions Daniel H. Sterman, MD
10:50 am Brain metastases: New therapies, new insights Speaker Invited
11:10 am Managing the toxicities of combined modality therapy Maria Werner-Wasik, MD
11:30 am Discussion
11:45 am Lunch
Session VIII: Targeted therapies and immunomodulation
1:00 pm Antibodies: Cetuximab, bevacizumab and beyond Speaker Invited
1:20 pm New angiogenesis inhibitors and tyrosine kinase inhibitors in the treatment of NSCLC Speaker Invited
1:50 pm Vaccines: Are there realistic expectations? John J. Nemunaitis, MD
2:10 pm Promising new therapies in NSCLC: HDAC inhibitors; hedgehog inhibitors, TRAIL antibodies, etc. Speaker Invited
2:30 pm Panel discussion
2:50 pm Break
Session IX: Biomarkers
3:10 pm Debate: Which markers should we use to guide therapy with EGFR inhibitors? Biomarkers Roman Perez-Soler, MD Clinical markers Speaker Invited
3:50 pm Using biomarkers to predict the efficacy of antiangiogenic agents and other targeted therapies Afshin N. Dowlati, MD
4:15 pm Summary and adjournment Corey J. Langer, MD, FACP

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a109-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live